Skip to main content
. Author manuscript; available in PMC: 2021 Jan 12.
Published in final edited form as: Clin Cancer Res. 2016 Mar 21;22(14):3683–3694. doi: 10.1158/1078-0432.CCR-15-2323

Figure 4. Reduction of GTL-16 tumor growth and MET phosphorylation by PF02341066.

Figure 4.

(A) pY1235-MET:MET ratio and (B) pY1356-MET:MET ratio during daily treatment with PF02341066. Tumor samples were analyzed at 4 and 24 h after dose 1, then 4, 12 and 24 h after dose 4 (D4), 12 h after dose 5 (D5), and 4, 12, and 24 h after dose 10 (D10). Mean ± SD, all groups n = 2-6 per dose per time point. The dotted line indicates the LSC in pMET:MET ratio from the vehicle-treated group of 45%; changes larger than this are attributed to drug effect. (C) Absolute levels of full-length MET plotted over time following daily doses of 12.5 and 25 mg/kg PF02341066 or vehicle; data normalized to extracted protein.